US FDA panel to weigh Avastin in first-line breast cancer
This article was originally published in Scrip
Executive Summary
The US FDA's oncologic drugs advisory panel will consider two new first-line indications for Roche's (Genentech) anti-angiogenic Avastin (bevacizumab) in breast cancer at a 20 July meeting.